Sermorelin reconstitution combines two different questions: what the particular product specifies, and how to convert its concentration into volume. The volume calculation can be checked exactly. A generic recipe cannot establish the diluent, storage period or injection schedule for every formulation.
Which inputs determine the answer?
| Input | What it controls | What it does not establish |
|---|---|---|
| Total sermorelin amount, in mg or mcg | Amount available for the concentration calculation | The prescribed amount per administration |
| Specified diluent and final solution volume | The product's preparation and concentration | A universal recipe for all sermorelin products |
| Concentration, in mcg/mL | Volume corresponding to an amount in mcg | A storage deadline |
| Syringe calibration | Relationship between volume and scale markings | The number of micrograms in a unit without a concentration |
| Dispensing label's storage and beyond-use date | The instructions assigned to that preparation | A stability result transferable to a different formulation |
Is bacteriostatic water always the sermorelin diluent?
No single diluent follows from the peptide name. The historical Geref 50 product information on HPRA's official site describes a 50-microgram diagnostic ampoule supplied with 0.9% sodium chloride solvent and prepared immediately before use. That is a specific historical formulation, not a mixing instruction for a current compounded vial.
The Hospira bacteriostatic-water label describes a multiple-dose diluent and lists presentations with either 0.9% or 1.1% benzyl alcohol. It assigns the vehicle and dilution volume to the instructions for the drug being dissolved. A water-vial label therefore does not supply the missing sermorelin formulation instructions.
How does the concentration calculation work?
For an example with a stated final solution volume of 2 mL and 3 mg of sermorelin: 3 mg = 3,000 mcg; 3,000 mcg / 2 mL = 1,500 mcg/mL. If the specified final volume is 3 mL instead, the concentration is 1,000 mcg/mL. These are arithmetic scenarios, not selected mixing volumes.
From the FormBlends catalog
Sermorelin
Bioidentical GHRH analog for natural growth hormone pulsatility · From $175/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sermorelin →The general equations are: concentration = total amount / final volume; volume = specified amount / concentration. For a syringe calibrated at 100 units per mL (U-100), units = volume in mL x 100. The same scale mark represents different peptide amounts at different concentrations.
| Example inputs | Calculated concentration | 20 U-100 units = 0.20 mL | Volume equivalent of a hypothetical 200 mcg |
|---|---|---|---|
| 3 mg, final volume 2 mL | 1,500 mcg/mL | 300 mcg | 0.13333 mL = 13.333 U-100 units |
| 3 mg, final volume 3 mL | 1,000 mcg/mL | 200 mcg | 0.20 mL = 20 U-100 units |
| 6 mg, final volume 2 mL | 3,000 mcg/mL | 600 mcg | 0.06667 mL = 6.667 U-100 units |
| 6 mg, final volume 4 mL | 1,500 mcg/mL | 300 mcg | 0.13333 mL = 13.333 U-100 units |
The 200-mcg column holds the amount constant so the effect of concentration is visible. It does not choose a dose. Rounding 13.333 units to 13 units in the first scenario yields 195 mcg, a 5-mcg difference. This makes the arithmetic approximation explicit rather than presenting a rounded marking as an exact equivalent.
Does a 28-day rule establish sermorelin stability?
A preservative in a diluent and chemical stability of the dissolved peptide are different measurements. The bacteriostatic-water label does not establish a 28-to-30-day shelf life for every sermorelin mixture. The historical Geref 50 information describes immediate preparation and use for its diagnostic ampoule. Neither source supplies formulation-specific stability data for an arbitrary compounded vial.
The date and storage conditions attached to the dispensed preparation are therefore separate inputs from the concentration calculation. A correct mcg/mL result cannot be used to calculate a beyond-use date.
What did the cited nightly-injection study actually measure?
Vittone and colleagues studied 11 men aged 64 to 76 over six weeks. Nightly GHRH 1-29 increased measured nocturnal growth-hormone release, while IGF-I levels and measured body composition did not change. Some strength measures improved. This small before-and-after study does not demonstrate a general fat-loss outcome or a preferred mixing recipe.
The distinctions matter: a hormone response, an IGF-I response, a body-composition change and product stability are separate outcomes. The Corpas citation is a review of growth hormone and aging (PMID 8491152), not a 112-person sermorelin trial.
Frequently asked questions
How many units are in a 3 mg sermorelin vial?
A vial's mass alone does not determine syringe units. With a stated final volume of 2 mL, 3 mg gives 1,500 mcg/mL, or 15 mcg per U-100 unit. With 3 mL, it gives 10 mcg per U-100 unit. The total vial contains 3,000 mcg in either scenario.
Does 20 units always equal 300 mcg?
Twenty U-100 units is 0.20 mL. It corresponds to 300 mcg at 1,500 mcg/mL, 200 mcg at 1,000 mcg/mL, and 600 mcg at 3,000 mcg/mL.
Does the water's preservative percentage determine the dose?
No. The peptide amount and final solution volume determine concentration. Preservative concentration describes a different property of the vehicle.
Is a nightly-injection study a reconstitution study?
No. The Vittone study measured hormonal, strength and body-composition outcomes. It did not test competing diluents or storage periods for current compounded preparations.
Sources used for this comparison
- HPRA-hosted historical Geref 50 product information, printed 2006, formulation and preparation sections.
- DailyMed: Hospira bacteriostatic water label, description and dilution sections.
- Vittone et al., 1997, PMID 9005976, human study abstract.
- Corpas et al., 1993, PMID 8491152, review publication type.
Footer Disclaimers
Platform: FormBlends provides informational content intended for educational purposes. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting any peptide therapy.
Research Compound / Compounded Medication Notice: Sermorelin is not currently available as an FDA-approved drug in the United States as of the date of this publication. Compounded sermorelin is prepared by licensed 503A or 503B compounding pharmacies and dispensed pursuant to a valid patient-specific prescription. Compounded products are not FDA-approved and have not been evaluated for safety, efficacy, or quality by the FDA.
Results Disclaimer: Individual results vary. The clinical trial data cited on this page were conducted in defined patient populations (adults with documented GH deficiency or elderly men with low-normal GH). These results may not apply to GH-sufficient adults using sermorelin for wellness purposes.
Trademark Notice: All product names, trademarks, and registered trademarks mentioned on this page are the property of their respective owners. FormBlends is not affiliated with or endorsed by any referenced manufacturer or compounding pharmacy.
Related peptide guides
Ready when you are
Sermorelin
Bioidentical GHRH analog for natural growth hormone pulsatility · From $175/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Sermorelin →